Nebulized in-line endotracheal dornase alfa and albuterol administered to mechanically ventilated COVID-19 patients: A case series

[1]  M. Neurath,et al.  Vascular occlusion by neutrophil extracellular traps in COVID-19 , 2020, EBioMedicine.

[2]  M. Raftery,et al.  Devilishly radical NETwork in COVID-19: Oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression , 2020, Advances in Biological Regulation.

[3]  R. V. Vander Heide,et al.  Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans , 2020, The Lancet Respiratory Medicine.

[4]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[5]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, The Lancet.

[6]  R. Becker.  COVID-19 update: Covid-19-associated coagulopathy , 2020, Journal of Thrombosis and Thrombolysis.

[7]  A. Schrum,et al.  Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome , 2020, New Microbes and New Infections.

[8]  M. Tay,et al.  The trinity of COVID-19: immunity, inflammation and intervention , 2020, Nature Reviews Immunology.

[9]  J. Marini,et al.  Management of COVID-19 Respiratory Distress. , 2020, JAMA.

[10]  R. Woods,et al.  Neutrophil extracellular traps in COVID-19. , 2020, JCI insight.

[11]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[12]  D. Brodie,et al.  Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study , 2020, medRxiv.

[13]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[14]  J. M. Crawford,et al.  Targeting potential drivers of COVID-19: Neutrophil extracellular traps , 2020, The Journal of experimental medicine.

[15]  S. Merler,et al.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. , 2020, JAMA.

[16]  C. Weber,et al.  Programmed ‘disarming’ of the neutrophil proteome reduces the magnitude of inflammation , 2020, Nature Immunology.

[17]  M. Cosentino,et al.   β2‐Adrenoceptors inhibit neutrophil extracellular traps in human polymorphonuclear leukocytes , 2018, Journal of leukocyte biology.

[18]  B. Mallavia,et al.  Maladaptive role of neutrophil extracellular traps in pathogen-induced lung injury. , 2018, JCI insight.

[19]  Z. Werb,et al.  Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. , 2012, The Journal of clinical investigation.

[20]  A. Zychlinsky,et al.  Neutrophil Elastase Enhances Sputum Solubilization in Cystic Fibrosis Patients Receiving DNase Therapy , 2011, PloS one.

[21]  J. Hartwig,et al.  Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. , 2011, Blood.

[22]  C. Morris,et al.  Use of dornase alfa in the management of ARDS , 2004, Anaesthesia.

[23]  Arthur S Slutsky,et al.  ARDSNet lower tidal volume ventilatory strategy may generate intrinsic positive end-expiratory pressure in patients with acute respiratory distress syndrome. , 2002, American journal of respiratory and critical care medicine.

[24]  J. Greenland,et al.  COVID-19 Infection: Implications for Perioperative and Critical Care Physicians , 2020 .

[25]  S. Nolan,et al.  Dornase alfa for cystic fibrosis. , 2017, Paediatric respiratory reviews.

[26]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..